Kiniksa Pharmaceuticals

Quarterly Financials

Values in thousands2026-03-312025-12-312025-09-302025-06-30
Revenue
$214,266
$202,127
$180,855
$156,797
Gross Profit
117,893
111,031
97,264
85,763
EBITDA
29,735
23,736
27,541
20,518
EBIT
29,267
23,269
27,157
20,160
Net Income
22,592
14,199
18,435
17,832
Net Change In Cash
214,266
202,127
180,855
156,797
Free Cash Flow
50,038
53,260
33,006
27,925
Cash
189,952
165,596
174,858
192,037
Basic Shares
82,409
78,979
78,027
77,942

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$677,564
$423,239
$270,259
$220,180
Gross Profit
370,150
362,329
213,735
197,285
EBITDA
90,422
-43,921
-22,855
12,175
EBIT
88,868
-45,616
-25,196
9,773
Net Income
59,005
-43,193
14,084
183,363
Net Change In Cash
677,564
423,239
270,259
220,180
Cost of Revenue
245
Free Cash Flow
25,412
25,412
13,171
5,702
Cash
165,596
183,581
107,954
122,715
Basic Shares
78,979
71,424
71,922
70,421

Earnings Calls

QuarterEPS
2026-03-31
$0.27
2025-12-31
$0.17
2025-09-30
$0.23
2025-06-30
$0.23